Tirzepatide for Obesity Treatment and Diabetes Prevention
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. METHODS: We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods. RESULTS: At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo). Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001). After 17 weeks off treatment or placebo, 2.4% of the participants who received tirzepatide and 13.7% of those who received placebo had type 2 diabetes (hazard ratio, 0.12; 95% CI, 0.1 to 0.2; P<0.001). Other than coronavirus disease 2019, the most common adverse events were gastrointestinal, most of which were mild to moderate in severity and occurred primarily during the dose-escalation period in the first 20 weeks of the trial. No new safety signals were identified. CONCLUSIONS: Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prediabetes to type 2 diabetes by 66-93% compared with placebo.65,75,76”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [76]
In the citing paper
“Tirzepatide administered at doses of 5, 10, and 15 mg once weekly in adjunct with a behavioral intervention comprising an energy-deficit diet and increased physical activity appears to be even more effective, with absolute weight losses of 15.0%, 19.5%, and 20.9% after 72 weeks in the SURMOUNT-1 trial 31 that was largely maintained when treatment was continued in a subset of participants for 176”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“SURMOUNT-1 showed the NNT with tirzepatide to prevent one case of T2D was 9 patients.”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“This stepwise approach anchored in trial evidence strengthens confidence in the validity and applicability of the current results, reinforcing the role of GLP-1-based therapies beyond previously established benefits in the evolving management of cardiometabolic HFpEF.54,56-62”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [62]
In the citing paper
“the reversal in glycemic benefits in HbA1c and FSG were observed early on within 16 weeks of withdrawing tirzepatide likely due to the known direct glucose-lowering effect of tirzepatide”
From Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial (2026) · cites this paper as [18]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citation2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Self-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Cited by
Items 101–200 of 443
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112294 · Cited by 12
Cowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S., & Calvo, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01761-4 · Cited by 13
“Tirzepatide has shown significant reductions in HbA1c levels and considerable weight loss among both patients with and without diabetes and obesity [47, 50, 51].”
Huang, S. Y., Tamaroff, J. G., Farber‐Eger, E. H., Chow, N., Siddiqi, H. K., Brinkley, D. M., Menachem, J. N., Rali, A. S., Lindenfeld, J. M., Ooi, H., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102710 · Cited by 17
Maracle, B., Quan, S., Hamilton, P., Shaikh, A., Hazra, D., Lorenzetti, D., Gold, S. L., Raman, M., & St‐Pierre, J. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70485 · Cited by 19
Troshina, E. A., Antsiferov, M. B., As, A., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2025) · Problems of Endocrinology · doi:10.14341/probl13677 · Cited by 14
“8) [42, 43].”
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Self-citationTamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 11
“Dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists, such as tirzepatide, are already used in clinical practice for diabetes and obesity [91].”
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
“When multiple publications originated from the same clinical research program, the most recent or most comprehensive report was used as the primary source.”
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“Consistently, during the same period, mean HbA 1c increased by 0.2%, with an estimated 50% loss of tirzepatide effect on glycaemic control after 4 months of discontinuation 97 .”
InfluentialCardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Tirzepatide for Obesity Treatment and Diabetes Prevention
Birkenfeld, A. L., Bergman, M., & Stefan, N. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2504728 · Cited by 9
Richardson, K. M., Schembre, S. M., Jospe, M. R., Widmer, A., & Silver, H. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16395 · Cited by 13
Lim, B. S. Y., Chen, M., Li, H., & Li, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16442 · Cited by 9
“58 Compared with metformin, even with its well-established efficacy, tirzepatide has demonstrated superior glycaemic control and significant weight reduction in clinical trials.”
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
“The SURMONT program includes five randomized double-blind phases 3 controlled trials with a duration of at least 72 weeks [46,48–52].”
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Jiang, N., Yin, J., Lawrence, N., Meng, J., Maeyens, L. T., Xu, Z., Li, X., Ekane, M., Chaudhary, A., Cao, P., et al. (2025) · Aging Cell · doi:10.1111/acel.70210 · Cited by 8
Tirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 23
Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide
Rzepiński, Ł., Tywoniuk, A., Jaraczewska, J., Al-Shaer, A., & Wiciński, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412028 · Cited by 8
“Furthermore, fewer participants in the tirzepatide groups received a diagnosis of T2D than in the placebo group (1.3% vs. 13.3%; p < 0.001) [4–6].”
InfluentialJansson, A. K., Gómez‐Martín, M., Hedin, L. E., Clarke, E. D., Cross, V., Stanford, J., Taylor, R., Bogl, L. H., de Vlieger, N., Koochek, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70077 · Cited by 13
Duodenal mucosa resurfacing: the endoscopic silver bullet against metabolic disorders?
Lonardo, A., & Singal, A. K. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.130 · Cited by 6
Weight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Choi, H.-I., Jeong, H. C., Jeong, J., Lee, J., Kim, D. H., Ko, K., Chae, Y., & Lee, K. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124836 · Cited by 7
Hong, A. T., Lin, F., Baxter, S. L., & Weinreb, R. N. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.12.003 · Cited by 8
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Feng, X., Li, S., Li, J., & Su, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003919 · Cited by 7
“[158] Tirzepatide is generally well-tolerated.”
Pharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6
“…of SURMONT-1, fewer participants received a diagnosis of T2DM in the tirzepatide groups than in the placebo group at 176 weeks (1.3% versus 13.3%); after 17 weeks off treatment or placebo, 2.4% of the participants who received tirzepatide and 13.7% of those who received placebo had T2DM [82].”
InfluentialA treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial
le Roux, C. W., Busetto, L., Aronne, L. J., Horn, D. B., Dimitriadis, G. K., Falcón, B. L., García‐Pérez, L., Valderas, E. G., Gibble, T. H., Şenyücel, Ç., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70531 · Cited by 5
“24 28 Baseline BMI subgroups were a prespecified stratification factor, and exploratory analysis suggests this characteristic may be relevant to defining TtT thresholds.”
Self-citationOcular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes
Hong, A. T., Lin, F., Keenan, J. D., & Stewart, J. M. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.02.002 · Cited by 9
Real-world efficacy of tirzepatide in patients with heart failure without diabetes
Augusto, S. N., Kaelber, D. C., & Tang, W. H. W. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.102998 · Cited by 8
“14 The SURPASS-CVOT trial compared the cardiovascular safety and efficacy of tirzepatide against dulaglutide in patients with T2DM and atherosclerotic cardiovascular disease (ASCVD), a population traditionally at a very high risk.”
Koufakis, T., Patoulias, D., Apostolopoulou, M., Georgianos, P. I., & Popovic, D. S. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2559907 · Cited by 5
“Clinical studies have reported a higher incidence of hypoglycemia and gastrointestinal adverse events with tirzepatide compared to semaglutide [25–27].”
Expanding applications of GLP-1 therapies: a careful view
Azzolino, D., & Lucchi, T. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01788-4 · Cited by 4
“The long-term ef fi cacy in sustaining weight loss and delaying progression to type 2 diabetes in persons with both obesity and prediabetes, has been also recently documented by the 3-year safety and ef fi cacy outcomes with tirzepatide (SURMOUNT-1 trial) [2].”
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
“…the efficacy of both oral semaglutide and orforglipron for weight loss, it also appears that the total weight loss is less than what can be obtained with injectable molecules, 129,137 such as semaglutide 6 and tirzepatide, 138 and they still report gastrointestinal AEs as the main complication.”
Barbosa, L. A. D. S., Almarie, B., & Moreira, E. L. G. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00875-y · Cited by 6
“…drugs for this pathway, aligning with recent clinical successes such as the approval of tirzepatide (a GLP-1/GIP agonist) for obesity and the development of retatrutide (a GLP-1/GIP/glucagon triagonist), which has demonstrated unprecedented weight loss in early clinical trials [15, 16].”
Argano, C., Orlando, V., Maggio, D., Pollicino, C., Torres, A., Cangialosi, V., Manno, S. B., & Corrao, S. (2025) · Metabolites · doi:10.3390/metabo15120773 · Cited by 6
Luca, M. D., COHEN, R. V., Belluzzi, A., Navarra, G., Lorenzo, N. D., Petry, T. B. Z., Sbraccia, P., Busetto, L., Buscemi, S., Barazzoni, R., et al. (2026) · Obesity · doi:10.1002/oby.70083 · Cited by 5
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
“The dual treatment led to a mean body weight reduction at 176 weeks of 12.3% in adult patients and delayed progression to type 2 diabetes [395,396].”
InfluentialiCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
“In the 3-year extension of SURMOUNT-1 amongst participants with prediabetes, mean weight reductions at 176 weeks were − 12.3% with tirzepatide 5 mg, − 18.7% with 10 mg and − 19.7% with 15 mg, compared with − 1.3% in the placebo group [100].”
InfluentialSelf-citationMerhi, Z. O. (2026) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeag015 · Cited by 6
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Rangraze, I. R., El-Tanani, M. E.-T., Janež, A., Maggio, V., Rabbani, S. A., Jensterle, M., Munda, A., Abbas, E. E., Ali, H. S., Farooqi, M. R., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01868-2 · Cited by 5
“In the pivotal SURMOUNT‑1 trial, mean body weight reduction reached − 20.9% after 72 weeks with tirzepatide 15 mg, and this effect was sustained during its 36‑week open‑label extension phase [2, 3].”
InfluentialMind the Plateau: A Mathematical Modeling Analysis of Long-Term GLP-1 Receptor Agonist Treatment
Hubert, P. A., Coleman, C. D., Grosicki, G. J., Kiel, J., Shepherd, M., Lofton, H. F., Heymsfield, S. B., Thomas, J. G., Dhurandhar, N. V., & Jonnalagadda, S. S. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156366 · Cited by 6
Lim, S. K., Nam, G. E., & Sharma, A. M. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0278 · Cited by 6
“…like the Semaglutide Treatment Effect in People with Obesity (STEP) series with semaglutide [59,60], and the SURMOUNT series with tirzepatide [61,62], and the Swedish Obese Subjects study [63] have confirmed the effectiveness of lifestyle interventions, pharmacotherapy, and surgery, yet…”
Ellberg, C. C., Schwartz, H. R., Witt, A., McCowen, K. C., Fuentes, A. L., & Malhotra, A. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00384-1 · Cited by 6
“Jastreboff et al. have published a number of prominent studies regarding tirzepatide therapy for obesity [44, 45].”
Coon, S. A., White, R. T., Pagnozzi, D., & Cowart, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16349 · Cited by 6
Manchanda, Y., Jones, B. J., Carrat, G., Ramchunder, Z., Marchetti, P., Leclerc, I., Thennati, R., BURADE, V. S., Natarajan, M., Shahi, P. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16652 · Cited by 5
Jensterle, M., & Janež, A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2554668 · Cited by 5
“Tirzepazide was also shown to reverse prediabetes and delay type 2 diabetes as well as improve OSA [9,10].”
Use of incretin-based therapies in women using hormone replacement therapy (HRT)
Mukherjee, A., Ghaem-Maghami, S., & Syed, A. A. (2025) · Post Reproductive Health · doi:10.1177/20533691251343069 · Cited by 3
“These medications result in significantly greater weight loss compared with placebo 12,13 and improvement in HbA1c in patient with diabetes 14 .”
Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?
Lang, K. (2025) · BMJ · doi:10.1136/bmj.q2636 · Cited by 4
Zhao, L., Tao, F., Cheng, Z., Lu, Y., Liu, M. R., Chen, H., Zhang, M., Yang, Y., Song, X. H., Sun, Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16439 · Cited by 3
“23 People with prediabetes have a higher-than-normal glycaemic level and are at an elevated risk of developing T2D compared to those with normoglycaemia.”
Pharmacological management of sleep apnea and obesity, a new frontier
Taweesedt, P. T., Orakpo, N., & Pelayo, R. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11798 · Cited by 3
Aranaz, P., Clavel-Millan, M., Gil‐Cardoso, K., González-Arceo, M., Hernández-González, D., Les, F., Salles, J., Amri, E., Arbonés-Mainar, J. M., Atgié, C., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01130-6 · Cited by 5
“Among them, dual agonists of glucose-dependent insulino-tropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, such as tirzepatide, or single GLP-1 analogs (semaglutide) have shown significant efficacy in promoting weight loss and improving glycemic control [9, 92].”
Valério, C. M., Saraiva, J. F. K., Valente, F., van de Sande‐Lee, S., Rocha, V. Z., Rached, F. H., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01954-8 · Cited by 11
Self-citationGenome-wide meta-analysis with 2,206,440 individuals identifies 322 novel risk loci for obesity
Gao, R., Su, W., Deng, J., Zhai, B., Zhu, G., Qiu, J., Bian, Z., He, X., Luan, G., & Wang, R. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01979-z · Cited by 4
El‐Amawy, H. S. (2025) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2025.501255 · Cited by 12
Ehrmann, D., Litterbach, E., Deschênes, S. S., Forde, R., Hermanns, N., Horsselenberg, M., Jansen, M., McInerney, A. M., Morrissey, E. C., SCHMITT, A. J., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70206 · Cited by 4
“…diabetes therapy has dramatically changed over the last 10 years and will continue to change due to technological (e.g. continuous glucose monitoring [CGM], automated insulin delivery [AID]), 15 pharmacological (e.g. incretin-based therapies) 16,17 and artificial intelligence 18,19 innovations.”
Weight loss drugs are effective, but can healthcare systems afford them?
West, S., Koutoukidis, D. A., & Jebb, S. A. (2026) · BMJ · doi:10.1136/bmj.s24 · Cited by 3
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“In the 3-year extension of SURMOUNT-1 among participants with prediabetes, mean weight reductions at 176 weeks were -12.3% with tirzepatide 5 mg, -18.7% with 10 mg, and -19.7% with 15 mg, compared with -1.3% in the placebo group [100].”
InfluentialSelf-citationZhang, Y., Zhang, C., gong, X., cheng, P., Fu, H., Diao, L., & Song, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-03933-9 · Cited by 13
“Among these agents, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as the particularly promising class, exhibiting robust weight loss effects [8, 9].”
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
“A subsequent analysis of the SURMOUNT-1 trial found that the mean weight loss sustained over 3 years was 12.3% with the 5 mg dose, 18.7% with the 10 mg dose, and 19.7% with the 15 mg dose [76].”
InfluentialMini-review. Vitamin D for the prevention of type 2 diabetes: Evidence and implications
Amrein, K., Kim, S. H., Brath, H., Fasching, P., & Pittas, A. G. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156566 · Cited by 5
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Schmickl, C. N., Tripipitsiriwat, A., Mokhlesi, B., Mallampalli, M. P., Nokes, B. T., Kundel, V., Page, K., Finch, C. E., Donovan, L. M., Tadros, M., et al. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-025-00024-0 · Cited by 6
“In the SURMOUNT trials [24 , 25 , 30 ], one year of tirzepatide led to ~ 20% weight loss, which in the SURMOUNT-OSA study [ 25] translated to a ~ 55% reduction in OSA sever - ity.”
Self-citationAronne, L. J., Horn, D. B., Kokkinos, A. D., Falcón, B. L., Wang, H., Hoffmann, H. T., Lee, C. J., & Dunn, J. P. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.03.010 · Cited by 6
Self-citationCoca, A., Sanchez, R., SALAZAR, D. I. M. D., Peñaherrera, E., Alcocer, L., Barbosa, E., Grassi, G. M., López-Jaramillo, P. A., Lurbe, E., Parra-Carrillo, J. Z., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004290 · Cited by 4
Salem, A., Ammar, A., Trabelsi, K., Boukhris, O. F., Heydenreich, J., Ghazzawi, H., Amawi, A. T., Grosso, G., Żmijewski, P., Jahrami, H., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1821389 · Cited by 5
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
“Tirzepatide, a dual GIP/GLP-1R agonist, has demonstrated efficacy in reducing body weight and limiting progression to type 2 diabetes in patients with obesity and predia-betes [397], suggesting that combined GIP/GLP-1 therapy may offer synergistic benefits in obesity-associated IBD.”
Pardeshi, G. S., Kumbhar, U. T., Kaviprawin, M., Debnath, A., Dubey, A. K., Deshmukh, K., Goyal, C., & Gandhi, A. P. (2025) · Clinical Obesity · doi:10.1111/cob.70042 · Cited by 4
“Of the three studies included, one was a Phase 2 double-blinded RCT, while the other two were retrospective cohort studies [14–16]”
Staats, P. S., Staats, A., Mikhaiel, B., Chen, J., Azabou, É., & Rangon, C.-M. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1644961 · Cited by 6
Prediabetes: a new indication for GLP-1s?
Apovian, C. M. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01930-2 · Cited by 4
“Dual-action on insulin sensitivity and the beta-cell might explain durability, but further studies are needed [6].”
InfluentialSardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.106951 · Cited by 6
Relapse in Anorexia Nervosa Associated With Tirzepatide: A Case Report
Guerdjikova, A. I., Dlugosz, H., Wolterman, R., & McElroy, S. L. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001975 · Cited by 5
Obstructive Sleep Apnoea Treatments—Where Are We Now?
Luu, S., Lee, D., & Yee, B. J. (2025) · Respirology · doi:10.1111/resp.70109 · Cited by 3
“It also reduced hypoxic burden, a physiologic measure that outperforms AHI in predicting cardiovascular and all-cause mortality [11]; and in non-OSA samples, improved various cardiometabolic outcomes [12–14].”
Xu, X., Zhang, Y., Geng, Y., Luo, Y., & Sun, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1650200 · Cited by 5
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., Valderas, E. G., Arad, A. D., Sharma, P., Dunn, J. P., Şenyücel, Ç., & Lee, C. J. (2025) · Obesity · doi:10.1002/oby.70014 · Cited by 3
Self-citationLingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Huang, H., Ou, Y., Lin, C. Y., & Lan, K. (2025) · Gynecology and Minimally Invasive Therapy · doi:10.4103/gmit.gmit-d-25-00082 · Cited by 3
“[53] c omPaRatIve e ffIcacy and m eta ‑ analytIc e vIdence Meta-analyses confirm the superior efficacy of GLP-1-based therapies.”
Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity?
Gisondi, P., Brigenti, N., Bellinato, F., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70208 · Cited by 2
Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
Martínez‐Castelao, A., Górriz, J. L., Fernández‐Fernández, B., Soler, M. J., & Navarro‐González, J. F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238326 · Cited by 4
Barenbaum, S. R., Aras, M., Kashyap, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf641 · Cited by 2
Self-citationThe Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism
Lin, A., Kitaura, H., Ohori, F., Marahleh, A., Ma, J., Fan, Z., Narita, K., Murakami, K., & KANETAKA, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020600 · Cited by 2
Tentolouris, A., Siafarikas, C., Ntanasis‐Stathopoulos, I., Anastasiou, I. A., Kalara, E., & Briasoulis, Α. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.01.003 · Cited by 3
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
The year in cardiovascular medicine 2025: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Marx, N., & Cannon, C. P. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehaf1125 · Cited by 2
Endogenous GIP signaling is indispensable for DPP ‐4 inhibitor‐mediated metabolic control in mice
Kubota‐Okamoto, S., Kubota, S., Tsuchida, H., Liu, Y., Banno, S., Imaizumi, T., Fujisawa, T., Takahashi, Y., Kato, T., Horikawa, Y., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70252 · Cited by 2
“GIP receptor agonists and GIP/GLP-1 dual receptor agonist tirzepatide have demonstrated robust glycemic and weight-lowering properties, leading to renewed interest in the physiological role of GIP in energy balance and glucose metabolism 7 – 9 .”
Schmidt, P. H. S., de Souza, V. S. N., Machado, L. G., Rodrigues, J. V. A., da Cruz, J. V. R., de Souza, L. S. N., dos Santos, B. E., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70529 · Cited by 8
“6,10 Although mechanistic data were not the focus of this analysis, the observed functional gains may be explained by increased mobility, decreased joint load, and enhanced physical confidence following significant weight reduction.”
Marko, D. M., Conn, M. O., Cavallari, J. F., Neudorf, H., Steele, A. P., Duggan, B. M., McAlpin, B. T., Barra, N. G., Hawke, T. J., Little, J. P., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117023 · Cited by 3
Nowak, M. Z., Núñez, L. M., Pagliaro, T., Robson, M. D., Duncker, C. M., Kaplan, L. M., Heymsfield, S., Thomaides-Brears, H. B., Bell, J. D., & Thomas, E. L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02037-y · Cited by 3
“…clinical trials with weight-loss treatments in individuals living with obesity or overweight are focused on sustaining weight lost after termination (wash-out) of treatment [30, 32], therefore our quanti fi cation of the changes in body composition with increase in body weight may be of relevance.”
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Bianchi, C., Prato, S. D., Rothberg, A. E., & Nauck, M. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70674 · Cited by 4
Aghemo, A., Armandi, A., Bugianesi, E., Cabibbo, G., Carbone, M., D’Ambrosio, R., Dalbeni, A., Cola, S. D., Gasbarrini, A., Germani, G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.014 · Cited by 4
GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K., & Lee, S. W. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70698 · Cited by 4
From the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
Holst, J. J. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.010 · Cited by 3
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro–con debate
Patel, S. R., & Ryan, S. (2026) · European Respiratory Review · doi:10.1183/16000617.0255-2025 · Cited by 3
“RCTs have demonstrated that tirzepatide reduces the risk of incident diabetes by a stunning 93%, while bariatric surgery leads to diabetes remission in 37% of patients (compared to 3% in controls) at 3 years [44, 45].”
Buonanno, S., Gaggiano, C., Baldi, C., Cantarini, L., Frediani, B., & Gentileschi, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060284 · Cited by 3
Hou, X., Chen, Y. H., Dong, W., Li, X., & Ji, S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1820776 · Cited by 5
Alfaris, N., Kushner, R. F., Li, J., Chen, K. L., Fenimore, M., Calderón, B., & Stefański, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70991 · Cited by 3
“In people with obesity and predia-betes, 3 years of tirzepatide treatment resulted in substantial, sustained weight reduction and lower risk of progression to T2D [14].”
Self-citationLeslie, D. B., Steffen, B. T., Wise, E., Steffen, L. M., Kopacz, K., Ruanpeng, D., Jacobs, D. R., & Ikramuddin, S. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00030-6 · Cited by 3
Metadata
- Authors
- Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., & Jouravskaya, I.
- Affiliations
- University College Dublin (IE)
- Eli Lilly, Indianapolis
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-06
- Volume
- 392
- Issue
- 10
- Pages
- 958-971
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404310616
- Semantic Scholar
- 6522eecd15e4fbb48021d492e79ee341ffc3540a
- Cited by
- 462
- References
- 41
- Citations by year
- 2026: 239 · 2025: 220
- FWCI
- 130.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- tirzepatide, obesity, prediabetes, type 2 diabetes prevention, weight loss, GIP/GLP-1 receptor agonist, long-term safety, diabetes onset, adverse events, drug discontinuation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Obesity, Prediabetic State, Weight Loss, Disease Progression, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.